Advances in Antibiotics & Antibodies
vol. 6 (2022), Article ID 101050, 2 pages
doi: 10.11131/AAACTV-22/101058

AgiAl Publishing House
http://www.agialpress.com/

Commentary

The Role of Antibiotics and its use in Antimicrobial Resistance

B. Astley*

Department of Antibodies, Monash University, Melbourne, Australia

Corresponding Author
B. Astley
astley@gmail.com

Editor
Jianlong Qiu

Dates
Received: 02-Aug-2022, Manuscript No. AAACTV-22-73520; Editor assigned: 05-Aug -2022, PreQC No. AAACTV-22-73520(PQ); Reviewed: 19-Aug -2022, QC No. AAACTV-22-73520; Revised: 26-Aug-2022, Manuscript No. AAACTV-22-73520(R); Published: 02-Sep-2022, DOI: 10.11131/AAACTV-22/101058

1. Description

Antibiotic use has made it possible to treat bacterial illnesses successfully, saving countless patients' lives and enhancing their health all around the world. Different health organizations have highlighted the establishment and spread of Antimicrobial Resistance (AMR) as a global problem and bacteria that are resistant to antibiotics significantly increase morbidity and mortality. As medication resistance rises, new potent treatments as well as preventative measures are required [1]. Vaccines are administered as a preventative measure, which lowers the incidence of infectious diseases, the need for antibiotics and the development and spread of AMR [2]. Antimicrobials have made it possible to treat infections that may be fatal, potentially saving lives and enhancing the health of countless patients around the world [3]. One of the biggest health problems today is the spread and growing prevalence of drug-resistant bacteria, which makes it harder to prevent and treat a variety of bacterial infections that were formerly curable [4]. Drug inadequacy and persistent infections brought on by the evolution of Antimicrobial Resistance (AMR) raise the risk of serious illness and transmission [5]. Antibiotic resistance is driven by a number and develops naturally, but the overuse of antimicrobials in the community context may have significantly speeded up the emergence and dissemination of new resistance mechanisms. Over the past few years, progresses have been made in emphasizing AMR as a threat to the health of the entire world. Focusing solely on research into the underlying processes of resistance and the creation of new antibiotics is insufficient given how quickly resistant has emerged to each new class of antibacterial introduced and the difficulties in creating new effective drugs. To effectively address AMR, a comprehensive approach that combines vaccinations with cutting-edge medicines, early diagnosis, monoclonal antibodies, micro biome manipulations and the use of bacteriophages is necessary. Progress has been made in recent years in emphasizing the threat that AMR poses to global health. How quickly resistance has developed to each new class of antibiotic released and the challenges in developing new efficient drugs, concentrating research into the underlying mechanisms of resistance and the development of new medicines is insufficient. A multifaceted strategy that incorporates vaccines with cutting-edge drugs, monoclonal antibodies and the use of bacteriophages is required to effectively combat AMR Single-chain Antibodies (mAbs). Since mAbs have been utilized as treatments for many years, they can be viewed as a crucial weapon in the fight against infections that are resistant to antibiotics and developing infectious illnesses mAbs bind to bacterial pathogens made by bacterial pathogens such as polysaccharides, toxins or effector proteins. These virulence factors can limit the target's function, promote complement mediated cell lysis or allow phagocytic effector cells to bacteria. There are numerous mAbs to bacterial infections that are resistant to antibiotics that are being developed at various phases. Antimicrobial susceptibility profiles are created using diagnostic methods to detect and characterize the microbial infections causing agents and to help choose the best course of therapy. Phenotypic and genotypic methods can be used for Antimicrobial Susceptibility Testing (AST). It can take up to 48 hours for AST to identify the causing substance and release a comprehensive and validated resistance profile allowing for the subsequent prescription of an effective therapy. Modern methods (such mass spectrometry) are being investigated in the search for faster AST, and some improvement based on the genomic details of a bacterial strain, reverse vaccinology permits the selection of possible vaccine candidates. The catalogue of genes that could potentially encode vaccine candidates that can be

chosen, screened and evaluated as vaccine possibilities is represented by a bacterium's whole genome. As a result, it is possible to identify immunogenic proteins that may be exposed to the surface in reverse. This method was used to create a B vaccine, which has been proven to be quite successful at preventing disease. To structurally help design protective and efficient vaccination antigens, immunological and functional evaluation of bacterial antigens can be integrated with structural knowledge. Improved antigens can be created by combining the ability to isolate barrier protection human monoclonal antibodies (from infected or immunized patients) with the knowledge of the structures of antigens and antigen-antibody complexes. This strategy makes use of the significantly improved capacity to clone human B cells and then to generate the relating recombinant monoclonal immunoglobulin or antigen-binding fragments. The acute viral virus F protein was stabilized in a particular conformation to produce a potent functional protective response in both animals and humans.

References

[1] Cherry JD. "Epidemic pertussis in 2012—the resurgence of a vaccine-preventable disease". N Engl J Med. vol.367, no.9, pp.785-787, 2012.

[2] Mooi FR, Van Oirschot H, Heuvelman K, van der Heide HG, Gaastra W and Willems RJ. "Polymorphism in the Bordetella pertussis virulence factors P. 69/pertactin and pertussis toxin in The Netherlands: temporal trends and evidence for vaccine-driven evolution". Infect Immun. vol.66, no.2, pp.670-675, 1998.

[3] Mishra RP, Oviedo-Orta E, Prachi P, Rappuoli R, and Bagnoli F. "Vaccines and antibiotic resistance". Curr Opin Microbiol. vol.15, no.5, pp.596-602, 2012.

[4] Miller E, Andrews NJ, Waight PA, Slack MP and George RC. "Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study". Lancet Infect Dis.vol.11, no.10, pp.760-768, 2011.

[5] Moore MR, Gertz, Jr RE, Woodbury RL, Barkocy-Gallagher GA, Schaffner W and Lexau C. "Population snapshot of emergent Streptococcus pneumoniae serotype 19A in the United States, 2005". J Infect Dis. vol.197, no.7, pp.1016-1027, 2008.